Latest News
-

AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-

Illuminating the progression of Huntington’s disease
6 min read
Researchers have used mice with glowing brain cells to decipher the first steps of neurodegeneration
-

Jumping genes: Huntington's disease protein invades brain transplants
6 min read
A long-term study of the brains of HD patients who received grafts of fetal tissue reveals a surprising result
-

The brain in Huntington's disease: greater than the sum of its parts?
6 min read
An important new study asks the question: what parts of the brain might need most help in HD?
-

NUB1: enhancing clearance to decrease mutant huntingtin
5 min read
NUB1 increases mutant huntingtin removal from cells, reducing the toxic effects of HD in fruit flies
-

Raptor announces results of cysteamine trial for Huntington's disease
10 min read
Raptor Pharmaceuticals announces intermediate results from a long-term study of cysteamine in Huntington's disease
-

Sleep, cilia and HD
9 min read
New studies shed some light on the function of sleep in animals, with interesting implications for HD research
-

Huntington's Disease Therapeutics Conference 2014: day 3
8 min read
Biomarkers and preparing for trials: the third & final day of the 2014 Huntington's Disease Therapeutics Conference
-

Huntington's Disease Therapeutics Conference 2014: day 2
5 min read
Cells, circuits and systems: day 2 of the 2014 HD Therapeutics conference
-

Huntington's Disease Therapeutics Conference 2014: day 1
10 min read
HDBuzz reports from the opening day of science sessions at the 2014 HD Therapeutics Conference in Palm Springs.

